Phase III trial of the anti-angiogenic agent thalidomide in patients with malignant mesothelioma after first line chemotherapy

Authors
Category Primary study
Registry of TrialsISRCTN registry
Year 2006
This article has no abstract
Epistemonikos ID: a772943384b913f53150893e31536d626d44c115
First added on: Jan 17, 2025